# Commiphora molmol

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/commiphora-molmol
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Myrrh, Myrrha, Commiphora myrrha, Balsamodendron myrrha, Gum myrrh, Somali myrrh, Heerabol myrrh, Molmol, Murr, Bola, Mo yao

## Overview

Commiphora molmol, commonly called myrrh, is a resinous gum containing sesquiterpenes (including furanoeudesma-1,3-diene) and terpenoids that drive its [anti-inflammatory](/ingredients/condition/inflammation) and [antimicrobial](/ingredients/condition/immune-support) actions. Its oleo-gum-resin interacts with opioid receptors and inhibits pro-inflammatory mediators, forming the basis of its traditional and emerging clinical applications.

## Health Benefits

• Minor mouth ulcers and oral inflammation - Traditional use recognized by EMA for oromucosal application (traditional evidence)
• [Antimicrobial](/ingredients/condition/immune-support) activity - Preclinical studies show effectiveness against S. aureus (MIC 0.18-2.8 µg/ml), E. coli, and C. albicans (preliminary evidence)
• [Anti-inflammatory](/ingredients/condition/inflammation) effects - Reduces IL-6 and IL-8 production in gingival fibroblasts at 0.00001-0.001% concentrations (preliminary evidence)
• PGE2 suppression - Inhibits prostaglandin E2 production in fibroblasts without affecting NF-κB activation (preliminary evidence)
• Genoprotective effects - Animal studies show 45% reduction in lead-induced chromosomal aberrations (preliminary evidence)

## Mechanism of Action

The sesquiterpene furanoeudesma-1,3-diene binds to opioid receptors, contributing to analgesic and [anti-inflammatory](/ingredients/condition/inflammation) effects. Myrrh's terpenoid fraction inhibits NF-κB signaling, suppressing downstream cytokines including TNF-α and IL-6. Additionally, the resin's volatile oil disrupts microbial cell membrane integrity, accounting for its broad-spectrum [antimicrobial](/ingredients/condition/immune-support) activity against S. aureus (MIC 0.18–2.8 µg/ml), E. coli, and Candida albicans.

## Clinical Summary

Evidence for Commiphora molmol is largely preclinical and based on traditional use recognized by the European Medicines Agency (EMA) for oromucosal applications such as minor mouth ulcers and gingival [inflammation](/ingredients/condition/inflammation). In vitro studies demonstrate consistent [antimicrobial](/ingredients/condition/immune-support) activity against gram-positive and gram-negative bacteria as well as fungi, though human randomized controlled trials are limited in number and sample size. One small clinical study examining myrrh-based mouthwash showed measurable reductions in plaque and gingival indices, but larger, well-controlled trials are needed to confirm efficacy and establish standardized dosing. Overall, evidence quality is classified as traditional or preliminary, and robust phase III clinical data are not yet available.

## Nutritional Profile

Commiphora molmol (myrrh) is a resin-gum exudate, not a nutritional food ingredient, so conventional macronutrient profiling is not applicable in the traditional sense. However, its chemical composition is well-characterized: Resin fraction (25-40% of dry weight) contains terpenoids including sesquiterpenes (α-bisabolol, furanoeudesma-1,3-diene, lindestrene) and triterpenes (α- and β-amyrin, taraxasterol); Gum fraction (57-65% of dry weight) is a water-soluble polysaccharide composed of arabinose, galactose, xylose, and glucuronic acid residues — contributing minor carbohydrate content but not nutritionally significant at typical doses; Essential oil fraction (2-8% of dry weight) contains sesquiterpene hydrocarbons (curzerene ~17%, β-elemene, δ-elemene) and furanosequiterpenes (furanodiene, furanodienone); Bioactive phenolic compounds include eugenol and ferulic acid at trace concentrations (<0.1%); Proteins and lipids are negligible (<1% combined); No clinically relevant vitamins or dietary minerals are present at meaningful concentrations; Typical therapeutic preparations use 1-5% myrrh tincture or dry extract equivalent to 300-600 mg crude resin; Bioavailability of terpenoid actives is moderate, enhanced by lipid-based carriers; oromucosal application bypasses first-pass [metabolism](/ingredients/condition/weight-management), improving local bioavailability for oral health applications.

## Dosage & Preparation

Tincture (1:5 in 90% ethanol) for oromucosal or cutaneous use in treating minor mouth ulcers and [inflammation](/ingredients/condition/inflammation). No specific daily doses are established in clinical studies. Product must comply with European Pharmacopoeia monograph 01/2008:1349. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Commiphora molmol is generally well tolerated at typical oromucosal doses, but may cause allergic contact dermatitis in sensitized individuals, and topical preparations can occasionally produce localized burning or irritation. It should be avoided during pregnancy, as myrrh has historically demonstrated uterotonic properties that may stimulate uterine contractions. Myrrh may interact with anticoagulants such as warfarin by potentially altering clotting parameters, and caution is warranted in patients taking hypoglycemic agents given preliminary evidence of [blood glucose](/ingredients/condition/weight-management)-lowering activity. Patients with known resin or Burseraceae family allergies should avoid use entirely.

## Scientific Research

No human clinical trials or meta-analyses were identified in the research dossier. The EMA/HMPC assessments indicate insufficient clinical data for well-established use, with support limited to traditional use for minor oral conditions. All efficacy data comes from preclinical studies including [antimicrobial](/ingredients/condition/immune-support) assays and cell culture models.

## Historical & Cultural Context

Myrrh has been used for over 2,000 years in traditional medicine systems including Ayurvedic, Unani, and Middle Eastern/Ancient Egyptian practices for treating wounds, mouth ulcers, [inflammation](/ingredients/condition/inflammation), and microbial infections. The EMA recognizes traditional herbal medicinal product status based on 30+ years of safe use in the EU.

## Synergistic Combinations

Frankincense, propolis, sage, chamomile, echinacea

## Frequently Asked Questions

### What is Commiphora molmol used for?

Commiphora molmol (myrrh) is primarily used as an oromucosal remedy for minor mouth ulcers, gum inflammation, and pharyngitis, a use formally recognized by the EMA under traditional herbal medicine provisions. Preclinical research also supports its antimicrobial activity against pathogens including S. aureus and Candida albicans, and its anti-inflammatory properties linked to NF-κB inhibition.

### What is the active compound in myrrh resin?

The primary bioactive sesquiterpene in myrrh is furanoeudesma-1,3-diene, which has been shown to interact with opioid receptors and contribute to analgesic effects. The resin also contains other terpenoids and volatile oils responsible for its antimicrobial and anti-inflammatory actions, with the exact composition varying by species and extraction method.

### How do you use myrrh for mouth ulcers?

The EMA-recognized traditional use involves applying a myrrh tincture (typically 5–10% in ethanol) directly to the affected oral mucosa up to three times daily, or using it as a diluted mouthwash rinse. It should not be swallowed in large quantities, and use should be limited to a maximum of two weeks without medical supervision if symptoms do not resolve.

### Is myrrh safe to take during pregnancy?

Myrrh is contraindicated during pregnancy due to documented uterotonic properties; animal studies and historical ethnobotanical records indicate it can stimulate uterine contractions, raising the risk of miscarriage or premature labor. The EMA also advises against use during pregnancy and breastfeeding due to insufficient safety data, and pregnant individuals should consult a healthcare provider before any use.

### Does myrrh interact with any medications?

Myrrh may potentiate the effects of anticoagulant medications such as warfarin by influencing platelet aggregation and coagulation cascades, increasing bleeding risk. Preliminary evidence also suggests possible additive hypoglycemic effects when combined with antidiabetic drugs like metformin or insulin, requiring blood glucose monitoring if used concurrently.

### What is the most effective form of Commiphora molmol for oral health?

Myrrh resin extract for oromucosal (mouth) application is the traditional form supported by EMA monographs for treating minor mouth ulcers and oral inflammation. Tinctures and rinses allow direct contact with affected oral tissues, which is more effective than systemic ingestion for localized mouth problems. The EMA recognizes this traditional use based on historical evidence of efficacy and safety when applied topically to the mouth.

### Who should avoid using Commiphora molmol supplements?

Individuals with severe kidney disease should avoid myrrh supplements, as traditional use data indicates potential concerns with renal function in compromised populations. Patients on anticoagulant medications (blood thinners) should consult their healthcare provider before use, as myrrh may have mild antiplatelet properties. Those with known allergies to plants in the Burseraceae family should avoid myrrh products.

### How strong is the scientific evidence for Commiphora molmol's antimicrobial claims?

Preclinical laboratory studies demonstrate that myrrh resin has antimicrobial activity against common oral bacteria (S. aureus, E. coli) and Candida albicans, with MIC values ranging from 0.18–2.8 µg/mL depending on the pathogen. However, these are in vitro findings that have not yet been consistently validated in large-scale human clinical trials, so claims about oral antimicrobial benefits remain preliminary. The EMA's traditional use recognition is based primarily on historical evidence rather than modern clinical data, indicating that more robust human studies are needed.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*